Background: Lysophosphatidic acid receptor 1 (LPAR1) has been identified as a biomarker in various cancer types. However, its biological function in papillary thyroid carcinoma (PTC) remains unknown.
Methods: LPAR1 was identified as a key regulator of epithelial-mesenchymal transition (EMT) in PTC cells through bioinformatics analysis of TCGA and GEO datasets. PPI analysis and correlation with immune infiltrates were also conducted. LPAR1 expression was evaluated using Gepia2 and GTEx, and miRNA target gene prediction was done with multiMiR. To assess the expression of LPAR1, we extracted total RNA from both the BCPAP cell line and the normal human thyroid epithelial cell line Nthy-ori 3-1. The levels of LPAR1 expression were then measured using quantitative real-time polymerase chain reaction (qRT-PCR) in the BCPAP cell line, with a comparison to the Nthy-ori 3-1 cell line.
Results: 1081 genes were upregulated, and 544 were downregulated compared to normal tissue. LPAR1 was identified as a key candidate by analyzing the TCGA and GEO datasets. PPI data analysis showed interactions with metastasis-related proteins. Functional enrichment analysis indicated involvement in signaling pathways like phospholipase D and actin cytoskeleton regulation. LPAR1 expression correlated positively with immune infiltrates such as CD4 T cells, macrophages, neutrophils, and myeloid dendritic cells but negatively with B cells. Additionally, miR-221-5p was predicted to target LPAR1 in PTC. Furthermore, our experimental data demonstrated that LPAR1 was under-expressed in the PTC cell line compared to the nonmalignant one ( < .01).
Conclusion: LPAR1 suppresses metastasis and is linked to EMT, as evidenced by the decreased LPAR1 expression and increased miR-221-5p in PTC. This suggests its potential as a biomarker for diagnosis and prognosis and as a therapeutic target for EMT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382228 | PMC |
| http://dx.doi.org/10.1177/11769351241277012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting the Hippo and Rap1 signaling pathways: the anti-proliferative effects of curcumin in colorectal cancer cell lines.
Med Oncol
January 2025
Department of Medical Surgical Nursing, College of Nursing, Princess Nourah bint Abdulrahman University, P.O. Box 84428, 11671, Riyadh, Saudi Arabia.
CRC has the third-highest cancer incidence and death. Many human cancers, including colorectal cancer, are connected to abnormal signaling pathway gene expression. Many human malignancies include Hippo and Rap1 signaling.
View Article and Find Full Text PDFThe Effects of Dexamethasone on Human Lens Epithelial Cells and the Analysis of Related Pathways with Transcriptome Sequencing.
Front Biosci (Landmark Ed)
November 2024
Department of Ophthalmology, University-Town Hospital of Chongqing Medical University, 401331 Chongqing, China.
Background: The goal of this study was to investigate the effects of dexamethasone on human lens epithelial cells (HLECs) and the potential mechanisms.
Methods: HLECs (HLE-B3) were cultured to assess the effects of dexamethasone on cell size at different concentrations. Immunofluorescence staining was used to detect specific protein expression in HLE-B3 cells.
Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning.
Sci Rep
November 2024
Department of Gastroenterology and Hepatology, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
Article Synopsis
- Colorectal polyps are potential early indicators of colorectal cancer, and this study focuses on the link between metabolic dysfunction associated steatohepatitis (MASH) and these polyps through biomarker analysis.
- The research utilized techniques like differential gene expression and co-expression network analysis, identifying 49 common genes that are primarily involved in apoptosis, proliferation, and infection.
- Key biomarkers (S100P, FOXO1, and LPAR1) were found to correlate with MASH and colorectal polyps, with machine learning validating these findings and suggesting potential small molecule compounds for chemoprevention.
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
J Med Chem
November 2024
Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States.
Article Synopsis
- Researchers discovered a strong and selective antagonist for the lysophosphatidic acid receptor 1 (LPAR1), which has antifibrotic properties, initially validated through a specific assay involving MRTF-A.* -
- Structural modifications improved the compound's stability and pharmacokinetics, leading to a promising candidate for oral dosing that effectively blocked LPA-induced histamine release and showed efficacy against lung fibrosis in preclinical tests.* -
- Despite its potential, the development of the LPAR1 antagonist was discontinued due to observed CNS toxicity in dog models, raising safety concerns for clinical use in idiopathic pulmonary fibrosis (IPF).*
Deficiency of lysophosphatidic acid receptor 3 decreases erythropoietin production in hypoxic mouse kidneys.
Lipids Health Dis
November 2024
The Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, Department of Biology, College of Life Sciences, Beijing Normal University, Beijing, 100875, China.
Background: Lysophosphatidic acid (LPA) is a lipid mediator with diverse biological functions through its receptors on the cell membrane. As one of the six LPA receptors, LPA receptor 3 (LPAR3) is highly expressed in mouse kidneys, but its physiological function in the kidney has been poorly explored.
Methods: Wild-type (WT) and Lpar3 mice were used to investigate the renal physiological function of LPAR3 under hypoxia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!